This Reckitt Benckiser spinout isn’t in the same territory as the pharma majors, but its story contains many familiar elements: blockbuster drugs, battles with regulators, pipeline problems, US ...

A value-oriented menu figures to be disproportionately important in the near term, with consumers seeking out relative value against a persistent inflationary backdrop. Darden's cautious approach to ...

We recently published a list of 10 Best Magic Formula Stocks for 2025. In this article, we are going to take a look at where ...

Marqeta is in a very strong financial position, ending December 2024 with around $1.1 billion in cash and investment securities on its balance sheet. With no long-term debt outstanding, this provides ...